NCT01866293View on ClinicalTrials.gov

Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

May 28, 2013

Primary Completion Date

August 18, 2016

Study Completion Date

August 18, 2016

Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
DRUG

Cabozantinib (XL184)

Trial Locations (5)

10065

Memorial Sloan Kettering Cancer Center, New York

10591

Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center, Sleepy Hollow

11570

Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre

11725

Memorial Sloan Kettering Cancer Center @ Suffolk, Commack

Unknown

Memoral Sloan Kettering Cancer Center, Basking Ridge

Sponsors

Collaborators (1)

Exelixis
All Listed Sponsors
collaborator

Exelixis

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER